Medexus Pharmaceuticals (MEDXF) Stock Price, News & Analysis

Company Overview

Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on acquiring, commercializing and supporting differentiated prescription products in North America. The company serves healthcare providers and patients primarily in the United States and Canada, with an emphasis on products addressing specialty and underserved therapeutic markets.

Medexus’ portfolio has included IXINITY, a recombinant factor IX replacement therapy used to prevent and control bleeding in people with hemophilia B; Rasuvo, a single-dose subcutaneous methotrexate injection used for certain rheumatoid arthritis and juvenile idiopathic arthritis patients; and Gleolan, an oral diagnostic imaging agent used during surgery to help visualize malignant glioma tissue.

The company’s business model is centered on licensing, acquiring and commercializing pharmaceutical products rather than conducting broad-based drug discovery. Medexus works with healthcare professionals, specialty pharmacies and other distribution partners to support product access and patient treatment across its target markets. The company is headquartered in Canada and has historically expanded its portfolio through product acquisitions and commercial partnerships.

Key Stats

• Today's Range: $3.53 to $3.56
• 50-Day Range: $3.34 to $3.82
• 52-Week Range: $1.80 to $3.96
• Volume: 1,030 shs
• Average Volume: 13,084 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:MEDXF
• CIK: N/A
• Web: www.medexus.com
• Phone: (514) 344-8765
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A